Oppenheimer Asset Management Inc. Viking Therapeutics, Inc. Transaction History

Oppenheimer Asset Management Inc.

  • $8.04 Billion
  • Q3 2024

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 02, 2022
SELL
$4.6 - $6.72 $67,224 - $98,206
-14,614 Closed
0 $0
Q3 2021

Nov 12, 2021
SELL
$5.58 - $7.04 $1,662 - $2,097
-298 Reduced 2.0%
14,614 $92,000
Q2 2021

Aug 03, 2021
SELL
$5.19 - $6.73 $845 - $1,096
-163 Reduced 1.08%
14,912 $89,000
Q1 2021

May 17, 2021
SELL
$5.74 - $9.67 $2,479 - $4,177
-432 Reduced 2.79%
15,075 $95,000
Q4 2020

Feb 11, 2021
SELL
$5.3 - $6.71 $1,340 - $1,697
-253 Reduced 1.61%
15,507 $87,000
Q3 2020

Nov 13, 2020
SELL
$5.73 - $8.11 $2,979 - $4,217
-520 Reduced 3.19%
15,760 $92,000
Q2 2020

Aug 11, 2020
BUY
$4.35 - $8.08 $1,187 - $2,205
273 Added 1.71%
16,280 $117,000
Q1 2020

May 08, 2020
SELL
$3.45 - $7.95 $993 - $2,289
-288 Reduced 1.77%
16,007 $75,000
Q4 2019

Feb 07, 2020
SELL
$6.38 - $8.73 $2,628 - $3,596
-412 Reduced 2.47%
16,295 $131,000
Q3 2019

Oct 31, 2019
SELL
$6.55 - $8.6 $1,820 - $2,390
-278 Reduced 1.64%
16,707 $115,000
Q2 2019

Aug 09, 2019
SELL
$7.67 - $10.63 $20,586 - $28,530
-2,684 Reduced 13.65%
16,985 $141,000
Q1 2019

Apr 24, 2019
SELL
$7.58 - $9.94 $52,741 - $69,162
-6,958 Reduced 26.13%
19,669 $196,000
Q4 2018

Jan 30, 2019
BUY
$7.16 - $16.21 $190,649 - $431,623
26,627 New
26,627 $204,000

Others Institutions Holding VKTX

# of Institutions
480
Shares Held
66.2M
Call Options Held
6.24M
Put Options Held
3.01M
View Full List

About Viking Therapeutics, Inc.

VKTX Quotes by TradingView
  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $5.25B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Oppenheimer Asset Management Inc. Portfolio

Follow Oppenheimer Asset Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Oppenheimer Asset Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Oppenheimer Asset Management Inc. with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email